| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.4802 |
| P698 | PubMed publication ID | 27577520 |
| P50 | author | Bart Vanhaesebroeck | Q64481959 |
| Neil J. Sebire | Q38549176 | ||
| P2093 | author name string | Sandra D Castillo | |
| P2860 | cites work | Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor | Q24291722 |
| Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas") | Q24292297 | ||
| Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2 | Q24310216 | ||
| A mosaic activating mutation in AKT1 associated with the Proteus syndrome | Q24598593 | ||
| Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome | Q24608709 | ||
| De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes | Q24627067 | ||
| Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy | Q24628724 | ||
| Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA | Q24632718 | ||
| Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo | Q24648140 | ||
| Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies | Q26866482 | ||
| Signaling pathways in the development of infantile hemangioma | Q26996608 | ||
| Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects | Q27333126 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Somatic Activating PIK3CA Mutations Cause Venous Malformation | Q28270654 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly | Q30647055 | ||
| Common and specific effects of TIE2 mutations causing venous malformations | Q30670028 | ||
| PHACE syndrome--clinical features, aetiology and management. | Q38607717 | ||
| Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review | Q38647921 | ||
| Molecules in medicine mini-review: isoforms of PI3K in biology and disease | Q38666875 | ||
| Pediatric Vascular Tumors and Malformations | Q38721126 | ||
| Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. | Q38941185 | ||
| Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin | Q39111280 | ||
| Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans | Q39875938 | ||
| AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo | Q40144983 | ||
| Histopathological reporting of paediatric cutaneous vascular anomalies in relation to proposed multidisciplinary classification system | Q40319578 | ||
| Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. | Q41791633 | ||
| Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. | Q42166673 | ||
| Angiosarcoma: clinical and molecular insights | Q43059257 | ||
| The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management | Q43232449 | ||
| Topical rapamycin (sirolimus) for facial angiofibromas | Q43246829 | ||
| Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor | Q43873032 | ||
| Localization of Tie2 and phospholipase D in endothelial caveolae is involved in angiopoietin-1-induced MEK/ERK phosphorylation and migration in endothelial cells | Q44532175 | ||
| Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo | Q46679054 | ||
| Congenital hemangiomas and infantile hemangioma: missing links | Q47577081 | ||
| Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity. | Q51178456 | ||
| Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. | Q52659903 | ||
| Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: evaluation of 126 cases. | Q53163727 | ||
| PI3K regulatory subunits lose control in cancer. | Q54705697 | ||
| Histopathological features of Proteus syndrome | Q57522602 | ||
| Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma | Q33408606 | ||
| Imaging of vascular tumors with an emphasis on ISSVA classification. | Q33410999 | ||
| Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation | Q33653132 | ||
| Vascular anomalies: A pictorial review of nomenclature, diagnosis and treatment | Q34251804 | ||
| Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma | Q34458738 | ||
| Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. | Q34509250 | ||
| A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 | ||
| Biology of infantile hemangioma | Q34867993 | ||
| PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting | Q35260766 | ||
| Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial | Q35470985 | ||
| Rapidly involuting congenital hemangioma: clinical and histopathologic features | Q35690061 | ||
| Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall | Q35967045 | ||
| Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease | Q36313189 | ||
| Arteriovenous malformations and other vascular malformation syndromes | Q36554606 | ||
| RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation | Q36745240 | ||
| Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling | Q36788733 | ||
| Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma | Q36995485 | ||
| Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. | Q37000488 | ||
| Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. | Q37078845 | ||
| Somatic PIK3CA mutations as a driver of sporadic venous malformations. | Q37130685 | ||
| Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations | Q37163303 | ||
| Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. | Q37275838 | ||
| Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system | Q37398561 | ||
| Kaposiform hemangioendothelioma | Q37425434 | ||
| Rapidly involuting congenital haemangioma (RICH) of the liver | Q37981096 | ||
| Development of PI3K inhibitors: lessons learned from early clinical trials | Q38080710 | ||
| Regulation of angiogenesis by PI3K signaling networks | Q38090346 | ||
| A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations | Q38105817 | ||
| Vascular anomalies in pediatric patients: updated classification, imaging, and therapy | Q38119716 | ||
| Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I). | Q38243260 | ||
| Genetics of hemangiomas, vascular malformations, and primary lymphedema | Q38249223 | ||
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 387-396 | |
| P577 | publication date | 2016-08-31 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies | |
| P478 | volume | 240 |
| Q33779469 | Hypoxia-inducible factor 1a induces phenotype switch of human aortic vascular smooth muscle cell through PI3K/AKT/AEG-1 signaling |
| Q90278154 | Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations |
| Q58798256 | The PI3K/AKT pathway in obesity and type 2 diabetes |
| Q99550277 | [Clinical effect of sirolimus in treatment of blue rubber bleb nevus syndrome in children: a report of 2 cases and literature review] |
Search more.